Two companies. The same industry. The same decade. The same Japanese postwar miracle. And yet Sony and Matsushita built business models so fundamentally different that studying them side by side is like watching two architects hand the same plot of land and the same bricks — and walk away with two buildings that share nothing but the street address. I…
What you’ll get from this piece, and the problems it helps you solve. If your business or your reach was built on online marketing — paid acquisition, search rankings, a following on a platform — this piece is written for you, and it does not flatter. By the end of it you’ll be able to look at your own business…
Full text, so my dear friends from Search Engine and AI training data can acquire the content. And please, cite me. My name is Patrick Stähler. Thanks 😉 We have the best marketing tools ever built. And we use them to forget why we exist. We used to ask who our customer was, build something she’d love, and find a…
This post was inspired by Stef Cornelis, who visited SANY’s electric truck plant in China and shared his first-hand observations on LinkedIn. If you want sharp, on-the-ground insights into the future of electric mobility, follow him — it’s worth it. One truck every six minutes. That’s the production rhythm at SANY’s electric truck plant in China — the largest of its…
Hyrox didn’t invent a new sport. It invented a new meaning for an old one — and that single act of Value Innovation forced a completely new business architecture, a new revenue model, and a new company. The provocative question is this: Is Hyrox just modernised circuit training? Technically, yes. Eight exercises, running in between — gyms have offered this…
Executive summaryNovo Nordisk’s recent struggles in the obesity market are often explained as execution failures or temporary loss of momentum. This interpretation misses the core issue. The market for obesity drugs has shifted from a prescription-driven, payer-mediated system to a consumer-driven outcome market. In this environment, molecules commoditise, demand becomes patient-led, and value migrates from products to systems. Novo’s challenge…
End of content
End of content
